GHB Divalproex Co-Administration via Segmented Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for narcolepsy, specifically sodium oxybate formulations like Xyrem, require dose reduction when co-administered with divalproex sodium due to pharmacokinetic and pharmacodynamic interactions, leading to increased systemic exposure and potential side effects such as impaired attention and memory.
Innovation Solution
A gamma-hydroxybutyrate composition is developed that can be concomitantly administered with divalproex sodium without reducing the dosage, utilizing a modified release formulation that minimizes drug-drug interactions, allowing for full doses of both medications to be taken without significant changes in systemic exposure or side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sodium oxybate is co-administered with divalproex sodium, then treatment efficacy for narcolepsy is improved, but systemic exposure increases leading to impaired attention and memory
Solution Approach 1:
The patent segments the sodium oxybate dosage into two distinct components: an immediate-release portion providing rapid absorption for acute symptom relief, and an extended-release portion providing sustained release to maintain therapeutic levels without excessive peak concentrations. This segmentation allows co-administration with divalproex sodium while avoiding the harmful pharmacokinetic interactions that occur with conventional single-dose formulations.
Solution Approach 2:
The patent employs a dynamic dosing strategy where the immediate-release and extended-release portions work in sequence to create a flexible pharmacokinetic profile. The immediate-release component addresses acute needs rapidly, while the extended-release component maintains steady therapeutic levels over time, adapting the drug's release characteristics to match the varying demands of narcolepsy treatment and minimizing interactions with divalproex sodium.
2Reliability
If full dosage of sodium oxybate is administered with divalproex sodium, then therapeutic effect is maintained, but dose reduction is required to avoid side effects
Solution Approach 1:
The patent divides the total daily dosage into immediate-release and extended-release portions, allowing the full therapeutic dose to be administered without exceeding safe peak concentration thresholds. The immediate-release portion provides rapid onset for acute symptom control, while the extended-release portion sustains therapeutic levels throughout the day, enabling full dosing with divalproex sodium while avoiding side effects through controlled release kinetics.
Solution Approach 2:
The patent changes the release rate parameter of the drug formulation by incorporating both immediate-release and extended-release mechanisms. This parameter modification allows the full therapeutic dosage to be delivered while controlling the rate of absorption, thereby maintaining efficacy without generating harmful side effects even when co-administered with divalproex sodium.
3Speed
If conventional sodium oxybate formulation is used, then rapid sleep onset is achieved, but dose adjustment is required when co-administered with divalproex sodium
Solution Approach 1:
The patent segments the dosage form into immediate-release and extended-release portions, where the immediate-release component ensures rapid sleep onset by quickly achieving therapeutic concentrations, while the extended-release component provides sustained coverage. This segmentation eliminates the need for dose adjustments when co-administered with divalproex sodium, as the controlled release profile inherently manages peak concentrations and minimizes pharmacokinetic interactions.
Solution Approach 2:
The patent ensures continuous therapeutic action through the combination of immediate-release and extended-release portions. The immediate-release component provides rapid initial effect for quick sleep onset, while the extended-release component maintains continuous therapeutic levels throughout the dosing interval. This continuous action profile allows consistent efficacy without requiring dose adjustments when taken with divalproex sodium.
Data Source
AI summary
Oral pharmaceutical compositions of gamma-hydroxybutyrate (GHB) suitable for concomitant administration with a dose of divalproex sodium (DVP) without materially altering the dosage amount of either drug are provided. Also provided are therapeutic uses of the compositions for the treatment of one or more symptoms of narcolepsy.